Clinical characteristics of all patients and patients from major subtypes
| . | All (n = 320) . | ALK+ (n = 78) . | ALK− (n = 113) . | PTCLU (n = 70) . | AITL (n = 28) . | Other (n = 31) . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 197 (61.6%) | 44 (56.4%) | 69 (61.1%) | 49 (70.0%) | 15 (53.6%) | 20 (64.5%) |
| Female | 123 (38.4%) | 34 (43.6%) | 44 (38.9%) | 21 (30.0%) | 13 (46.4%) | 11 (35.5%) |
| Median age, y (range) | 50 (18, 78) | 37 (18, 74) | 50 (18, 77) | 54 (20, 78) | 64 (22, 77) | 49 (18, 75) |
| Age > 60 y | 96 (30.0%) | 11 (14.1%) | 39 (34.5%) | 25 (35.7%) | 15 (53.6%) | 6 (19.4%) |
| LDH > UNV | 121 (37.8%) | 21 (26.9%) | 41 (36.3%) | 31 (44.3%) | 19 (67.9%) | 9 (29.0%) |
| ECOG > 1 | 53 (16.6%) | 11 (14.1%) | 16 (14.2%) | 12 (17.1%) | 8 (28.6%) | 6 (19.4%) |
| Stage III, IV | 163 (50.9%) | 41 (52.6%) | 49 (43.4%) | 37 (52.9%) | 23 (82.1%) | 13 (41.9%) |
| More than 1 extranodal site | 61 (19.1%) | 16 (20.5%) | 16 (14.2%) | 18 (25.7%) | 3 (10.7%) | 8 (25.8%) |
| IPI | ||||||
| 0, 1 | 163 (50.9%) | 45 (57.7%) | 64 (56.6%) | 32 (45.7%) | 6 (21.4%) | 16 (51.6%) |
| 2 | 80 (25.0%) | 21 (26.9%) | 27 (23.9%) | 16 (22.9%) | 8 (28.6%) | 8 (25.8%) |
| 3 | 48 (15.0%) | 10 (12.8%) | 14 (12.4%) | 12 (17.1%) | 7 (25.0%) | 5 (16.1%) |
| 4, 5 | 29 (9.1%) | 2 (2.6%) | 8 (7.1%) | 10 (14.3%) | 7 (25.0%) | 2 (6.5%) |
| B symptoms | 139 (43.4%) | 42 (53.8%) | 39 (34.5%) | 28 (40.0%) | 19 (67.9%) | 11 (35.5%) |
| Bulky disease | 82 (25.6%) | 23 (29.5%) | 35 (31.0%) | 12 (17.1%) | 2 (7.1%) | 10 (32.3%) |
| . | All (n = 320) . | ALK+ (n = 78) . | ALK− (n = 113) . | PTCLU (n = 70) . | AITL (n = 28) . | Other (n = 31) . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 197 (61.6%) | 44 (56.4%) | 69 (61.1%) | 49 (70.0%) | 15 (53.6%) | 20 (64.5%) |
| Female | 123 (38.4%) | 34 (43.6%) | 44 (38.9%) | 21 (30.0%) | 13 (46.4%) | 11 (35.5%) |
| Median age, y (range) | 50 (18, 78) | 37 (18, 74) | 50 (18, 77) | 54 (20, 78) | 64 (22, 77) | 49 (18, 75) |
| Age > 60 y | 96 (30.0%) | 11 (14.1%) | 39 (34.5%) | 25 (35.7%) | 15 (53.6%) | 6 (19.4%) |
| LDH > UNV | 121 (37.8%) | 21 (26.9%) | 41 (36.3%) | 31 (44.3%) | 19 (67.9%) | 9 (29.0%) |
| ECOG > 1 | 53 (16.6%) | 11 (14.1%) | 16 (14.2%) | 12 (17.1%) | 8 (28.6%) | 6 (19.4%) |
| Stage III, IV | 163 (50.9%) | 41 (52.6%) | 49 (43.4%) | 37 (52.9%) | 23 (82.1%) | 13 (41.9%) |
| More than 1 extranodal site | 61 (19.1%) | 16 (20.5%) | 16 (14.2%) | 18 (25.7%) | 3 (10.7%) | 8 (25.8%) |
| IPI | ||||||
| 0, 1 | 163 (50.9%) | 45 (57.7%) | 64 (56.6%) | 32 (45.7%) | 6 (21.4%) | 16 (51.6%) |
| 2 | 80 (25.0%) | 21 (26.9%) | 27 (23.9%) | 16 (22.9%) | 8 (28.6%) | 8 (25.8%) |
| 3 | 48 (15.0%) | 10 (12.8%) | 14 (12.4%) | 12 (17.1%) | 7 (25.0%) | 5 (16.1%) |
| 4, 5 | 29 (9.1%) | 2 (2.6%) | 8 (7.1%) | 10 (14.3%) | 7 (25.0%) | 2 (6.5%) |
| B symptoms | 139 (43.4%) | 42 (53.8%) | 39 (34.5%) | 28 (40.0%) | 19 (67.9%) | 11 (35.5%) |
| Bulky disease | 82 (25.6%) | 23 (29.5%) | 35 (31.0%) | 12 (17.1%) | 2 (7.1%) | 10 (32.3%) |